AstraZeneca Forecast, price target & analysts
AstraZeneca Target price 2026 - Analyst rating & recommendation
AstraZeneca Classifications & Recommendation
AstraZeneca Price Target
| Target Price | £163.20 |
| Price | £124.28 |
| Potential |
31.32%
register free of charge
|
| Number of Estimates | 30 |
|
30 Analysts have issued a price target AstraZeneca 2027 .
The average AstraZeneca target price is £163.20.
This is
31.32%
register free of charge
£212.10
70.66%
register free of charge
£66.79
46.26%
register free of charge
|
|
| A rating was issued by 35 analysts: 28 Analysts recommend AstraZeneca to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2027 of
31.32%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion £ | 44.31 | 49.09 |
| 8.63% | 10.78% | |
| EBITDA Margin | 30.93% | 36.13% |
| 1.08% | 16.80% | |
| Net Margin | 17.41% | 24.83% |
| 33.80% | 42.64% |
33 Analysts have issued a sales forecast AstraZeneca 2026 . The average AstraZeneca sales estimate is
This results in the following potential growth metrics:
25 Analysts have issued an AstraZeneca EBITDA forecast 2026. The average AstraZeneca EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
33 AstraZeneca Analysts have issued a net profit forecast 2026. The average AstraZeneca net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share £ | 4.94 | 7.86 |
| 45.72% | 59.11% | |
| P/E | 15.89 | |
| EV/Sales | 4.39 |
33 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is
This results in the following potential growth metrics and future valuations:
Current AstraZeneca Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | Jun 26 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Jun 26 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | Jun 02 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | May 21 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Jun 26 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Jun 26 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Jun 09 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Jun 02 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
May 21 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
